MENLO PARK, Calif. – SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company signed an agreement for BioCat GmbH to distribute the innovative LightSwitch Luciferase Assay System(TM) in Europe.

The system consists of a full reporter assay solution including a genome-wide collection of human promoter and 3’UTR luciferase reporters and optimized luciferase assay reagents for measuring transcriptional activation and translational efficiency in living cells.

“We are very excited to partner with BioCat to gain a broader exposure in Europe, a rapidly growing market for us,” said Nathan Trinklein, Ph.D., CEO and co-founder of SwitchGear Genomics, “The agreement furthers our effort to providing a full and cost-effective reporter assay solution using new channels.” Under the agreement, BioCat GmbH will promote and sell all components of the LightSwitch Luciferase Assay System in Germany, Austria, and Switzerland with full sales, marketing, and technical support from SwitchGear.

About SwitchGear Genomics, Inc.: SwitchGear Genomics Inc. is a leading provider of technologically innovative products for studying the regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory network, allowing researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr.

Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at www.switchgeargenomics.com SOURCE: SwitchGear Genomics Inc.

CONTACT: SwitchGear Genomics Nathan Trinklein, Ph.D., 650-323-6763 CEO and co-founder